You are here: Industry Insights > Cabometyx

News List

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carci firstwordpharma
August 26, 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono).
Opdivo plus Cabometyx approved in the EU for advanced renal cancer pharmatimes
April 01, 2021
The European Commission (EC) has authorised Bristol Myers Squibb’s (BMS) Opdivo plus Ipsen’s Cabometyx as a first-line treatment for advanced renal cell carcinoma (aRCC).
Evrysdi leads latest CHMP recommendations pharmatimes
March 02, 2021
The European Medicines Agency’s (EMA) Committee for Medicines for Human Use (CHMP) has recommended six medicines for approval at its February meeting.
Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck fiercepharma
January 17, 2019
Exelixis’ fast-growing tyrosine kinase inhibitor Cabometyx just added another FDA approval. It can now treat liver cancer patients if Bayer’s Nexavar is no longer helpful, putting it in a field that’s already crowded with Bayer’s Stivarga and some checkpo
Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck fiercepharma
January 17, 2019
Exelixis’ fast-growing tyrosine kinase inhibitor Cabometyx just added another FDA approval. It can now treat liver cancer patients if Bayer’s Nexavar is no longer helpful, putting it in a field that’s already crowded with Bayer’s Stivarga and some checkpo
Exelixis’ Cabometyx approved in second-line liver cancer in US pharmaphorum
January 16, 2019
Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.
Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma firstwordpharma
January 15, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc.(NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated wi
European Commission Approves Ipsen’s Cabometyx® for Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib americanpharmaceuticalreview
November 19, 2018
Ipsen announced that the European Commission (EC) has approved Cabometyx (cabozantinib) 20, 40, 60 mg as a monotherapy f
Ipsen’s Cabometyx wins EU nod for liver cancer pharmatimes
November 19, 2018
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Ipsen reveals positive Phase 2 data of Cabometyx in liver cancer pharmafile
July 06, 2018
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase II clinical trial of liver cancer drug Cabometyx (cabozantinib).

Previous page 1 2 Next page